Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Albiglutide

WITHDRAWN

GLP-1 receptor agonist

2
graded results
0
ongoing records
2
effect domains
Evidence spread
High evidence 1Moderate evidence 1Low evidence 0Very low evidence 0

Albiglutide has a withdrawn status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

WITHDRAWN European Union; Type 2 diabetes; Subcutaneous injection; as of 2026-07-13. European Medicines Agency

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Albiglutide WITHDRAWN
Heart and circulation Decrease
High evidence

In T2D with established CVD, albiglutide reduced MACE versus placebo, a superiority result driven notably by reduced myocardial infarction.

Hernandez AF et al., Lancet, 2018 Source
PopulationHARMONY Outcomes: N=9463; T2D with established CVD; double-blind placebo-controlled RCT; median 1.6 years (short).
Fundingindustry - GlaxoSmithKline
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Albiglutide WITHDRAWN
glycaemic Decrease
Moderate evidence

Once-weekly albiglutide (30/50 mg) monotherapy reduced HbA1c by approx 0.8% vs placebo (HARMONY 2); in HARMONY Outcomes it reduced MACE by ~22% vs placebo. Weight loss...

Hernandez AF et al., Lancet 2018 (HARMONY Outcomes); Reusch J et al., Diabetes Obes Metab... Source
Full findingOnce-weekly albiglutide (30/50 mg) monotherapy reduced HbA1c by approx 0.8% vs placebo (HARMONY 2); in HARMONY Outcomes it reduced MACE by ~22% vs placebo. Weight loss was modest and lower than competing GLP-1 RAs.
PopulationHARMONY 2: T2D inadequately controlled with diet/exercise, 52 weeks, placebo-controlled. HARMONY Outcomes: 9463 T2D with CV disease, median 1.6 years, vs placebo
Fundingindustry - GlaxoSmithKline
Comparatorsplacebo